Tacrolimus Extended-Release Oral Capsule
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease
Conditions
End Stage Renal Disease
Trial Timeline
Sep 11, 2017 → Oct 27, 2020
NCT ID
NCT03194321About Tacrolimus Extended-Release Oral Capsule
Tacrolimus Extended-Release Oral Capsule is a approved stage product being developed by Astellas Pharma for End Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03194321. Target conditions include End Stage Renal Disease.
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Disease were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03194321 | Approved | Completed |
Competing Products
20 competing products in End Stage Renal Disease